XORTX Therapeutics Showcases Advancements at Microcap Conference
CALGARY, Alberta — XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA) is proud to announce its attendance and presentation at the esteemed Microcap Conference hosted by DealFlow Events. This significant event takes place over several days, creating a vibrant platform for companies like XORTX to connect with investors. Notably, this year, XORTX is eager to share its insights and updates on its new gout program.
Key Presentation Details
During the conference, specifically on January 29, the company's presentation will focus on the advancement of its latest product, the XRx-026 program targeting gout, alongside details related to the XRx-008 program aimed at treating autosomal dominant polycystic kidney disease (ADPKD). Attendees can look forward to an in-depth review of XORTX's plans to file a New Drug Application (NDA) for gout treatments and prepare for clinical trials for ADPKD.
Engagement with Investors
Dr. Allen Davidoff, the CEO of XORTX Therapeutics, expressed enthusiasm about the opportunity this conference provides. “This conference is designed to facilitate one-on-one meetings with potential investors, allowing us to present a comprehensive overview of our company to all attendees. We’re excited to reach out to quality investors and to further elaborate on our promising plans for bringing our gout program into action soon, along with the ongoing development of our ADPKD treatments over a longer timeframe,” he commented.
XORTX's Innovative Product Pipeline
XORTX Therapeutics is dedicated to creating innovative therapies for patients living with chronic kidney ailments and gout. The company is focused on clinical developments related to its three advanced pharmaceutical products, namely: 1) XRx-008, specifically designed for ADPKD; 2) XRx-026, aimed at patients intolerant to allopurinol for gout; and 3) XRx-101, which targets acute kidney injury linked to COVID-19 infection. These therapies reflect the company’s goal of managing and improving the quality of life for patients suffering from these chronic conditions.
Commitment to Patient Health
Furthermore, XORTX is also working on a preclinical project, XRx-225, aimed at treating Type 2 Diabetic Nephropathy. The company's distinct approach in targeting aberrant purine metabolism and xanthine oxidase offers the potential to decrease or inhibit the production of uric acid. By focusing on these therapeutic areas, XORTX aims to make a substantial difference in the health and lives of kidney disease patients and those affected by gout.
Access to Presentation
XORTX’s presentation will be recorded and made accessible after the event on the company’s website, enabling broader audiences to stay informed about its developments and future directions.
Contact Information
For any inquiries, stakeholders can reach out to:
Allen Davidoff, CEO
Contact: adavidoff@xortx.com or +1 403 455 7727
Nick Rigopulos, Director of Communications
Contact: nick@alpineequityadv.com or +1 617 901 0785
Frequently Asked Questions
What is XORTX presenting at the Microcap Conference?
XORTX will present updates on its gout treatment and ADPKD programs during the Microcap Conference.
Who is the CEO of XORTX Therapeutics?
The CEO of XORTX Therapeutics is Dr. Allen Davidoff.
What are the main therapeutic areas XORTX focuses on?
XORTX focuses on progressive kidney disease and gout treatment innovations.
How can I access XORTX's conference presentation?
The presentation will be recorded and made available on the XORTX website after the conference.
What is the significance of the XRx-026 program?
The XRx-026 program is vital for treating patients who are intolerant to allopurinol, addressing a critical need in gout management.